AcelRx Pharmaceuticals PT Lowered to $16.00 (ACRX)
Jefferies Group decreased their price objective on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from $17.00 to $16.00 in a research note issued on Tuesday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price objective would suggest a potential upside of 148.06% from the company’s current price.
ACRX has been the subject of a number of other recent research reports. Analysts at Cowen and Company reiterated an “outperform” rating on shares of AcelRx Pharmaceuticals in a research note on Tuesday, July 29th. They now have a $14.00 price target on the stock, down previously from $15.00. Separately, analysts at Piper Jaffray downgraded shares of AcelRx Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Tuesday, July 29th. They now have a $8.00 price target on the stock, down previously from $14.00. Finally, analysts at JMP Securities cut their price target on shares of AcelRx Pharmaceuticals from $14.00 to $12.00 in a research note on Monday, July 28th. They now have an “outperform” rating on the stock. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $13.06.
AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down 4.81% during mid-day trading on Tuesday, hitting $6.14. 1,359,627 shares of the company’s stock traded hands. AcelRx Pharmaceuticals has a 52-week low of $6.04 and a 52-week high of $13.64. The stock has a 50-day moving average of $9.17 and a 200-day moving average of $10.38. The company’s market cap is $266.0 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. Analysts expect that AcelRx Pharmaceuticals will post $-1.02 EPS for the current fiscal year.
AcelRx Pharmaceuticals, Inc is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.